Centessa Pharmaceuticals (NASDAQ:CNTA) Sees Strong Trading Volume – Still a Buy?

Shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) saw unusually-high trading volume on Wednesday . Approximately 3,050,342 shares changed hands during mid-day trading, an increase of 39% from the previous session’s volume of 2,196,948 shares.The stock last traded at $39.8050 and had previously closed at $39.72.

Key Headlines Impacting Centessa Pharmaceuticals

Here are the key news stories impacting Centessa Pharmaceuticals this week:

• Positive Sentiment: Acquisition announced — Eli Lilly agreed to buy Centessa for $38 per share in cash plus a contingent value right (CVR) that can add up to $9, valuing the transaction at up to $7.8B. The takeover news drove an initial surge in CNTA shares. Eli Lilly to buy Centessa Pharma in $6.3 billion deal
• Positive Sentiment: Bullish options flow around the announcement — traders bought a large number of call options on March 31 (about 2,994 calls), indicating speculative/transaction-driven upside interest tied to the Lilly bid and potential deal outcomes. (internal trading data)
• Neutral Sentiment: Deal economics and structure — the headline $38 cash upfront values Centessa at roughly $6.3B initially, with the CVR creating upside tied to undisclosed milestones (up to $9 per share). That structure leaves some outcome risk pending milestone achievement and CVR terms. Eli Lilly to acquire Centessa in $6.3B deal to expand neuroscience portfolio
• Negative Sentiment: Analyst downgrades are pressuring the stock today — Needham, Wolfe Research and Stephens cut ratings (to hold), which often trims momentum after a takeover pop and can weigh on short‑term trading. Needham downgrades Centessa Pharmaceuticals plc – depositary receipt (CNTA)
• Negative Sentiment: Large put buying today — unusually heavy purchase of 10,659 put options (a +1,668% spike vs. typical), signaling hedging or bearish bets that can amplify downward pressure if traders roll positions or raise supply. (internal trading data)
• Negative Sentiment: Shareholder litigation and fairness probes — multiple law firms have launched investigations into whether the $38 offer is fair and whether the sale process was adequate; potential legal challenges or demands for a higher bid could prolong uncertainty. Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process
• Negative Sentiment: Recent earnings miss — Centessa reported an EPS miss for the latest quarter (‑$0.48 vs. consensus ‑$0.38), which weakens the company’s standalone fundamentals and gives critics leverage in fairness arguments. (internal earnings data)

Wall Street Analyst Weigh In

Several research firms have issued reports on CNTA. Needham & Company LLC cut shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday. Wolfe Research lowered Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating in a research note on Tuesday. Oppenheimer upped their target price on Centessa Pharmaceuticals from $40.00 to $62.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 10th. Stephens downgraded Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday. Finally, Truist Financial raised their target price on shares of Centessa Pharmaceuticals from $33.00 to $38.00 and gave the company a “buy” rating in a research note on Thursday, January 29th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $40.00.

Centessa Pharmaceuticals Stock Down 0.3%

The company has a market cap of $5.78 billion, a P/E ratio of -21.64 and a beta of 1.55. The stock has a 50-day moving average of $26.29 and a two-hundred day moving average of $25.24. The company has a debt-to-equity ratio of 0.36, a quick ratio of 10.57 and a current ratio of 10.56.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings results on Tuesday, March 31st. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.10). On average, research analysts anticipate that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Iqbal J. Hussain sold 38,951 shares of the stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $25.15, for a total transaction of $979,617.65. Following the completion of the sale, the insider directly owned 57,645 shares in the company, valued at $1,449,771.75. This represents a 40.32% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Gregory M. Weinhoff sold 73,196 shares of the firm’s stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $26.33, for a total value of $1,927,250.68. Following the transaction, the insider owned 65,925 shares in the company, valued at approximately $1,735,805.25. The trade was a 52.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 349,073 shares of company stock valued at $9,429,412 over the last three months. Insiders own 7.09% of the company’s stock.

Institutional Trading of Centessa Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Avoro Capital Advisors LLC increased its stake in shares of Centessa Pharmaceuticals by 116.2% in the third quarter. Avoro Capital Advisors LLC now owns 10,808,080 shares of the company’s stock worth $262,096,000 after buying an additional 5,808,080 shares during the period. EcoR1 Capital LLC boosted its position in Centessa Pharmaceuticals by 466.4% during the 4th quarter. EcoR1 Capital LLC now owns 3,115,000 shares of the company’s stock valued at $77,906,000 after buying an additional 2,565,000 shares during the period. Braidwell LP bought a new stake in Centessa Pharmaceuticals in the 4th quarter worth $54,730,000. Federated Hermes Inc. bought a new stake in Centessa Pharmaceuticals in the 3rd quarter worth $42,429,000. Finally, Maverick Capital Ltd. bought a new position in shares of Centessa Pharmaceuticals during the fourth quarter valued at about $41,110,000. Hedge funds and other institutional investors own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.